Particle-based platforms for malaria vaccines

被引:24
作者
Wu, Yimin [1 ]
Narum, David L. [1 ]
Fleury, Sylvain [2 ]
Jennings, Gary [3 ]
Yadava, Anjali [4 ]
机构
[1] NIAID, Lab Malaria Immunol & Vaccinol, Rockville, MD 20892 USA
[2] Mymetics Corp, CH-1066 Epalinges, Switzerland
[3] Cytos Biotechnol AG, CH-8952 Schlieren, Switzerland
[4] Walter Reed Army Inst Res, Malaria Vaccine Branch, US Mil Malaria Vaccine Program, Silver Spring, MD USA
关键词
Malaria; Vaccine; Particle; Delivery; Adjuvant; TRANSMISSION-BLOCKING VACCINE; AERUGINOSA EXOPROTEIN-A; IMMUNE-RESPONSES; ADJUVANT SYSTEM; THERAPEUTIC VACCINES; FALCIPARUM-MALARIA; EPITOPE DENSITY; IMMUNOGENICITY; CANDIDATE; DELIVERY;
D O I
10.1016/j.vaccine.2015.09.097
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Recombinant subunit vaccines in general are poor immunogens likely due to the small size of peptides and proteins, combined with the lack or reduced presentation of repetitive motifs and missing complementary signal(s) for optimal triggering of the immune response. Therefore, recombinant subunit vaccines require enhancement by vaccine delivery vehicles in order to attain adequate protective immunity. Particle-based delivery platforms, including particulate antigens and particulate adjuvants, are promising delivery vehicles for modifying the way in which immunogens are presented to both the innate and adaptive immune systems. These particle delivery platforms can also co-deliver non-specific immunostimodulators as additional adjuvants. This paper reviews efforts and advances of the Particle-based delivery platforms in development of vaccines against malaria, a disease that claims over 600,000 lives per year, most of them are children under 5 years of age in sub-Sahara Africa. (C) 2015 Elsevier Ltd.
引用
收藏
页码:7518 / 7524
页数:7
相关论文
共 70 条
[1]   Cationic Liposomes Formulated with Synthetic Mycobacterial Cordfactor (CAF01): A Versatile Adjuvant for Vaccines with Different Immunological Requirements [J].
Agger, Else Marie ;
Rosenkrands, Ida ;
Hansen, Jon ;
Brahimi, Karima ;
Vandahl, Brian S. ;
Aagaard, Claus ;
Werninghaus, Kerstin ;
Kirschning, Carsten ;
Lang, Roland ;
Christensen, Dennis ;
Theisen, Michael ;
Follmann, Frank ;
Andersen, Peter .
PLOS ONE, 2008, 3 (09)
[2]   Rapid antibody response after vaccination with a virosomal hepatitis A vaccine [J].
Ambrosch, F ;
Finkel, B ;
Herzog, C ;
Koren, A ;
Kollaritsch, H .
INFECTION, 2004, 32 (03) :149-152
[3]   Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60 Evaluation of immunogenicity, cross-protection, safety and tolerability [J].
Ansaldi, Filippo ;
Orsi, Andrea ;
de Florentiis, Daniela ;
Parodi, Valentina ;
Rappazzo, Emanuela ;
Coppelli, Martina ;
Durando, Paolo ;
Icardi, Giancarlo .
HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (03) :591-598
[4]  
Aucouturier J, 2002, VACCINE S2, V24
[5]   Therapeutic vaccines for chronic diseases: successes and technical challenges [J].
Bachmann, Martin F. ;
Jennings, Gary T. .
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES, 2011, 366 (1579) :2815-2822
[6]   Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns [J].
Bachmann, Martin F. ;
Jennings, Gary T. .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (11) :787-796
[7]   Malaria vaccine R&D in the Decade of Vaccines: Breakthroughs, challenges and opportunities [J].
Birkett, Ashley J. ;
Moorthy, Vasee S. ;
Loucq, Christian ;
Chitnis, Chetan E. ;
Kaslow, David C. .
VACCINE, 2013, 31 :B233-B243
[8]   Virosome-Formulated Plasmodium falciparum AMA-1 & CSP Derived Peptides as Malaria Vaccine: Randomized Phase 1b Trial in Semi-Immune Adults & Children [J].
Cech, Patrick Georges ;
Aebi, Thomas ;
Abdallah, Mwanajaa Shomari ;
Mpina, Maxmillian ;
Machunda, Ester Barnabas ;
Westerfeld, Nicole ;
Stoffel, Sabine Alexandra ;
Zurbriggen, Rinaldo ;
Pluschke, Gerd ;
Tanner, Marcel ;
Daubenberger, Claudia ;
Genton, Blaise ;
Abdulla, Salim .
PLOS ONE, 2011, 6 (07)
[9]  
Chroboczek J, 2014, ACTA BIOCHIM POL, V61, P531
[10]   Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-γ/IL-2 CD4+T cells but does not protect against experimental Plasmodium falciparum infection [J].
Cummings, James F. ;
Spring, Michele D. ;
Schwenk, Robert J. ;
Ockenhouse, Christian F. ;
Kester, Kent E. ;
Polhemus, Mark E. ;
Walsh, Douglas S. ;
Yoon, In-Kyu ;
Prosperi, Christine ;
Juompan, Laure Y. ;
Lanar, David E. ;
Krzych, Urszula ;
Hall, B. Ted ;
Ware, Lisa A. ;
Stewart, V. Ann ;
Williams, Jack ;
Dowler, Megan ;
Nielsen, Robin K. ;
Hillier, Collette J. ;
Giersing, Birgitte K. ;
Dubovsky, Filip ;
Malkin, Elissa ;
Tucker, Kathryn ;
Dubois, Marie-Claude ;
Cohen, Joe D. ;
Ballou, W. Ripley ;
Heppner, D. Gray, Jr. .
VACCINE, 2010, 28 (31) :5135-5144